Reciprocal chromosomal translocations are a hallmark of many B-cell lymphomas, and are frequently seen as recurrent abnormalities. As such, they appear to delineate specific subsets in individual lymphoma categories. Their occurrence also raises the question whether they might associate with distinct pathways of clonal origins or tumor behavior. The reciprocal translocations that juxtapose immunoglobulin (Ig) gene loci and proto-oncogenes are of particular interest, as they result in upregulated proto-oncogene expression, owing to translocated Ig enhancer elements. These types of translocations are important in diffuse large B-cell lymphoma (DLBCL), a disease that displays marked heterogeneity in presentation and outcome. Of note, the t(14;18)(q32;q21) and t(3;14)(q27;q32) translocations are two of the most frequent translocations observed in DLBCL. They dysregulate expression of the antiapoptotic protein BCL2, or the germinal center (GC) transcription factor BCL6, respectively, and it is thought that aberrant expression of these molecules may initiate distinctive pathogenetic mechanisms. 1 In order to track how defined chromosomal abnormalities may associate with specific tumor origins in DLBCL, investigators have recently begun to exploit insights emerging from gene expression profiles. 2 These profiles provide a means of classifying disease heterogeneity in DLBCL, and have defined three distinct tumor subtypes that have a prognostic and biological relevance. 2 The germinal center-B cell like (GCB) subset is characterized by an expression profile resembling that of normal GC B-cells. The activated-B-cell-like (ABC) profile is characterized by expression of genes normally induced during in vitro activation of B-cells, and Type 3 profiles represent expression of heterogeneous GCB or ABC genes. 2 In order to simplify the methodological requirement for identification of GC/non-GCB signatures in DLBCL, Hans et al. have established a cohort of genes that can be evaluated by immunohistochemistry (IHC). 3 They have shown that the IHC criteria can achieve a GC/non-GCB designation that is able to predict survival as well as complementary DNA microarray profiles. Classification of DLBCL with t(14;18)(q32;p21) or t(3;14)(q27;q32) by immunohistochemical criteria into GCB or non-GCB subtypes according to the algorithm proposed by Hans et al. Ig variable (V) region gene analysis provides another tier to analyze clonal origins in B-cell tumors, and there has been recent interest in coupling V gene features with gene expression profiles, to better understand tumor origins and biology. V gene analysis can readily identify if the cell of origin has entered the GC reaction, the general mechanism of somatic mutation (SM). The pattern of acquired mutations can provide additional insights. Remarkably, it is now established that in t(14;18) follicular lymphoma (FL), SM generates novel N-glycosylation sites in tumor V genes as a near universal event. 4 These sites are retained despite on-going mutational activity. 4 It has been suggested that the glycosylation sites in tumor V genes are an adaptive response to facilitate survival specifically in the GC. 4 The novel glycosylation motifs almost ubiquitously present in FL are in marked contrast to a frequency of o10% in normal circulating B-cells. 4 Interestingly, in DLBCL B40% of cases also show evidence for these motifs, but as yet it is not known which disease subset they may be associating with, if any, or what their role might be. 4 The first study which examined the hypothesis that the t(14;18) initiating event in DLBCL would associate with a GC B-cell gene expression profile found that the vast majority of t(14;18) DLBCL did indeed display GC profiles. 3 More recently, we have examined the association of t(14;18) with GC DLBCL further in the present report, using IHC criteria for subset identification. We confirm a GC phenotype, but also now report that the t(14;18) in DLBCL associates with a specific pattern of GC V gene use. In addition, we have examined DLBCL with clonal t (3;14) , where constitutive BCL6 expression in disease ontogeny would suggest a GC association, and report on differing patterns of Ig V gene usage in this disease subset.
For this study, 27 De novo DLBCL cases were selected from our lymphoma data base, which presented at initial diagnosis with either a t(14;18)(q27;q21) translocation (11 cases) or a t(3;14)(q27;q32) translocation (16 cases), as assessed by conventional cytogenetics. Involvement of BCL6 in all t(3;14) cases was confirmed by the presence of Im-BCL6 transcripts by reverse transcriptase-polymerase chain reaction, and the t(14;18) abnormality by amplification of the BCL2/JH translocation at the major breakpoint region.
De novo t(14;18) DLBCL associated predominantly with a GCB-phenotype as defined by the IHC decision tree 5 (a GCB phenotype is assigned when CD10 expression, both BCL6/CD10 expression, or BCL6 expression alone with MUM1 negativity are observed, shown schematically in Figure 1 ). By contrast, t(3;14) DLBCL cases were mainly CD10 negative, BCL6 positive and MUM1 positive, corresponding to a non-GCB phenotype in 75% of cases (Figure 1) .
In total, 21 tumor-derived V H were identifiable from 27 cases ( Table 1 ). In t(14;18) cases, 10 potentially functional V H genes were derived from V H 3 (9) and V H 4 (1). In t(3;14) cases, the most frequently identified gene was V 4-34 (7/11), suggesting asymmetry of V H gene usage. In previous studies, the preferential use of the V 4-34 gene in DLBCL has been a matter of debate. 6, 7 Our study now raises the possibility that this discrepancy may in part be related to the primary chromosomal translocation associated with the DLBCL cases, which had not been examined previously. V gene sequences revealed mutations in all cases. On-going SM, as assessed by intraclonal variation in tumor-derived V H sequences, was apparent in 2/10 cases with t(14;18), including one case (no. 6) with a non-GCB phenotype. In t(3;14) DLBCL, on-going mutational activity was found in 4/7 cases, including three with a non-GCB phenotype (Table 1) . When we examined the V gene mutation patterns for acquisition of novel glycosylation motifs, we found sites in 10 cases (nine in V H and one in V L ; Figure 2 ). Strikingly, 8/10 (80%) of t(14;18) DLBCL cases displayed a glycosylation motif, seven in V H and one in V L . In one t(14;18) case (no. 1), we failed to amplify a clonal V L -J L rearrangement, and we cannot exclude this motif in V L . This revealed a highly prevalent glycosylation motif in t(14;18) DLBCL, at a frequency comparable to the near universal acquisition of these sites in t(14;18) FL. 4 These data reinforce a GC-association of t(14;18) DLBCL which was apparent from gene expression profiles, and furthermore provide strong evidence for a common cell of origin linking de novo t(14;18) DLBCL and t(14;18) FL. 3 Although 7/8 motifs in t(14;18) cases correlated with a GCB phenotype, one t(14;18) non-GCB cases also revealed such a site (Table 1 ). In the latter case, it is possible that the criteria used for determining GCB/non-GCB by IHC may not be fully exacting, and that additional genes may be required to enable a robust designation.
It therefore appears that both the aggressive and more indolent forms of t(14;18) þ ve lymphoma require a glycosylated surface Ig receptor for survival in the GC. An intriguing postulate is that glycosylation may permit B-cell receptor activation via interactions with GC stromal lectins in FL, thereby bypassing a specific requirement for antigen. 4 Interestingly, glycosylation motifs were mainly acquired at the 5 0 -terminus of the CDR3 sequence in our DLBCL cases, in codons most likely derived from N-addition. At these sites, any germline donor V gene hot-spot influences are obviated. It suggests that CDR3 may be a key contact point for glycoprotein-mediated interactions.
The t(14;18) translocation is generated in the main during V(D)J recombination in early B-cell development, but is clearly insufficient for full neoplastic transformation. It has been suggested that acquisition of N-glycosylation motifs in t(14;18) FL may constitute a critical second neoplastic event, 4 and our findings suggests that this may also hold true for de novo t(14;18) DLBCL.
It is unclear whether the lower frequency of glycosylation motifs (2/10 cases; 20%) in de novo t(3;14) reflects the background level (B10%) seen in normal B-cells, as a limited number of cases were examined here. 4 However, another feature tends to argue that the low frequency of these motifs in t(3;14) DLBCL may indeed reflect normal background levels. The V 4-34 gene contains a natural N-glycosylation site in CDR2, Figure 2 Comparison of the deduced amino-acid sequences from patient-derived tumor V genes. Comparisons are made with the closest germline V H or V L gene. Only replacement mutations are indicated (uppercase letters). Dots represent identity with the corresponding germline sequence. Glycosylation motifs (N-X-S/T) generated by SMs are highlighted. and this site was lost by mutation in each of the seven t(3;14) DLBCL cases (Figure 2 ). This suggests an active de-selection mechanism operating against glycosylation motifs. Of the V 4-34 cases, 6/7 were non-GCB and one case GCB, reflecting the predominant non-GCB phenotype of t(3;14) DLBCL. The apparent biased selection of V 4-34 -expressing B-cells in these DLBCL may have further implications. The V 4-34 gene is of importance in autoimmune disease, such as in systemic lupus erythematosus and cold agglutinin disease (CAD). 8 It can mediate reactivity against self-antigens. V 4-34 encodes a unconventional framework-1 Cys-Ala-Val-Tyr (CAVY) motif in germline configuration, which mediates binding to N-acetyllactosamine determinants in surface glycoproteins found in blood cell I/i antigens, the basis of reactivity in CAD. 8 Recent data suggests that prevention of autoreactivity in health is regulated in part by excluding V 4-34 B-cells from forming mature GCs. 8 However, in V 4-34 þ DLBCL, we observed a significant level of SM, which in three out of five cases was on-going (Table 1 ). One possibility is that these lymphoma cells are derived from B cells that overcame specific peripheral tolerance checkpoints to enter the GC, but expanded at post-GC sites, and maintained constitutive mutational activity in many cases. Alternatively, mutation may have been initiated at non-GC sites, and as the CAVY motif was intact in 5/7 V 4-34 t(3;14) cases, it could potentially mediate unconventional tumor-stroma interactions to trigger mutational activity.
To conclude, our data reveal critical features of de novo t(14;18) and t(3;14) DLBCL, which show that tumor cells have orchestrated multiple molecular mechanisms to utilize their oncogenic potential and ensure survival at distinct sites.
